InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Discover the complete record of transactions filed by Meltzer Leslie, Chief Research and Development. Insider active across 2 companies, notably Apellis Pharmaceuticals, Inc.. Cumulatively, 3 disclosures have been published. History available since 26 August 2025. The latest transaction was filed on 28 January 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Meltzer Leslie
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
107,024 股Common StockSEC:0001193125-26-224620:0
45,220 股0Common StockSEC:0001492422-26-000075:0
61,804 股0Common StockSEC:0001127602-25-021056:0
3 条申报中的 3 条
About Meltzer Leslie
Leslie Meltzer is the Chief Research and Development Officer at Apellis Pharmaceuticals, Inc. In this role, she oversees the company's research and development initiatives, focusing on innovative therapies to treat serious diseases. Ms. Meltzer plays a key role in guiding research projects and collaborating with scientific teams to ensure the success of product developments.
